By Hilary Rosselot
Dr. Kathryn Argue Shares Information and Tips for Applying for DOD’s PRMRP Funding
The NFXF hosted a webinar featuring Dr. Kathryn Argue, Deputy Program Manager of the Peer Reviewed Medical Research Program. Dr. Argue reviewed the details of the Congressionally Directed Medical Research Program, specifically the Peer-Reviewed Medical Research Program (PRMRP). Fragile X is an eligible topic within the PRMRP, as has been for over a decade thanks to the tireless efforts of NFXF Advocates.
Dr. Argue shared programmatic details, deadlines, and tips to support researchers throughout the application process. Dr. Argue finished the webinar by answering questions from attendees.
A few top tips from Dr. Argue include:
- Read the funding opportunity announcement carefully.
- You do not need an invitation to apply for several of the funding opportunities.
- Be aware of the award-specific deadlines and submit on time—there are no exceptions.
- Align your proposal with the program-specific goals.
- Check the FY23 PRMRP Strategic Plan
- Fragile X sits in the Rare Diseases and Conditions Portfolio
- Fragile X includes all FMR1-associated conditions and disorders (FXS, FXTAS, FXPOI, Fragile X Premutation).
- While not new, hereditary ataxia is also listed as an eligible condition within the PRMRP, which may be a good option for FXTAS projects. Learn more.
Watch a recording of the webinar and view Dr. Argue’s slides below.
We are grateful for partners like the PRMRP who fund Fragile X research. Thank you, Dr. Argue, for taking the time to educate us about this valuable funding opportunity. If you have questions about the PRMRP, please email help@ebrap.org.
The NFXF is also here to help! If you would like to participate in the NFXF’s Research Readiness Program, consult with our Family Advisory Commitee, or partner in another way, please reach out to hilary@fragilex.org.
about
![Author Hilary Rosselot](https://fragilex.org/wp-content/uploads/Rosselot-Hilary-contact.jpg)
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
NFXF Webinar: 2021 Industry Updates
We held an NFXF Webinar with three of our industry partners working on treatments for Fragile X syndrome. Each shared the most up-to-date information on their research project(s) in a way that is understood by those who aren’t steeped in drug research day in and day out. A short Q&A followed each presentation.
Benefit of BPN14770 for Cognition and Daily Function in Fragile X Syndrome
Your summary of the results, including why it matters to you and next steps, from the Dr. Liz Berry-Kravis and Tetra Therapeutics BPN14770 trial results published in Nature Medicine. This was a randomized, double-blind, placebo-controlled, two-period crossover study.